ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/her2-low
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / HER2-low
4
trial(s) found.
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT05950945
Advanced
Phase 3
Recruiting
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-
HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low
or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) (
DS8201-0001-CIS-MA
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2060 - North Sydney - Mater Hospital (TERMINATED)
VIC
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (TERMINATED)
SA
5000 - South Australia - GenesisCare St Andrews Hospital (TERMINATED)
WA
6150 - Murdoch - Fiona Stanley Hospital (WITHDRAWN)
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Atirmociclib
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK4 selective inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Metformin
Nab-paclitaxel
PI3K alpha inhibitor
Palbociclib
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
biguanide antihyperglycaemic agent
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK4 selective-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
VIC (3)
WA (2)
NSW (1)
NZ (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (4)
Cancer Therapy Class
ERBB2
100%
AKT
25%
CD40
25%
CDK4
25%
CDK4 selective
25%
CDK6
25%
ER
25%
IL-6
25%
LIV1
25%
PD-1/PD-L1
25%
PD-L1
25%
PI3Kalpha
25%
Trop2
25%
VEGF
25%
oestrogen axis
25%
Facility
3199 - Frankston - Peninsula Health Frankston Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
NA
2060 - North Sydney - Mater Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
6009 - Nedlands - Linear Clinical Research (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gastrointestinal cancer
Oesophageal cancer
Thoracic cancer
Upper gastrointestinal cancer
Breast adenocarcinoma
HER2-low breast cancer
HER2-negative breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy